Insulet Co. (NASDAQ:PODD) Shares Acquired by Horizon Investments LLC

Horizon Investments LLC grew its position in Insulet Co. (NASDAQ:PODD) by 3.1% in the fourth quarter, HoldingsChannel reports. The fund owned 1,387 shares of the medical instruments supplier’s stock after acquiring an additional 42 shares during the quarter. Horizon Investments LLC’s holdings in Insulet were worth $362,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the fourth quarter worth about $36,000. SRS Capital Advisors Inc. raised its position in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares during the period. TD Private Client Wealth LLC raised its position in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the period. Friedenthal Financial acquired a new position in shares of Insulet in the fourth quarter worth about $57,000. Finally, Assetmark Inc. increased its stake in shares of Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 246 shares in the last quarter.

Insulet Stock Performance

Insulet stock opened at $265.39 on Friday. The firm has a 50 day simple moving average of $272.11 and a 200-day simple moving average of $256.26. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market cap of $18.64 billion, a price-to-earnings ratio of 45.84, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. On average, analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insider Transactions at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on PODD. TD Cowen boosted their target price on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Raymond James reissued an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Royal Bank of Canada began coverage on shares of Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. Stifel Nicolaus boosted their target price on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company boosted their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.